ArticleAmerican journal of translational research2021
Analysis of the correlation of the expression level of hypoxia-inducible factor-1α with the glycosylation of oral squamous cell carcinoma.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the correlation of the expression level of hypoxia-inducible factor-1α (HIF-1α) with the glycosylation of oral squamous cell carcinoma (OSCC).
methodsWe conducted an immunohistochemical SP method to detect the expression levels of HIF-1α and O-glycosylation-related proteins (O-linked N-acetylglucosamine [O-GlcNAc], O-GlcNAcase [OGA], and O-GlcNAc transferase [OGT]) in 30 cases of OSCC tissues that were surgically removed and confirmed by pathology in our hospital from January 2018 to July 2020. Meanwhile, the expression levels of O-GlcNAc, OGA, and OGT under the action of the HIF-1α inhibitor PX-478 were detected by Western blotting in the human OSCC cell line (Tca8113 line).
results① The expression of HIF-1α and O-glycosylation-related proteins in OSCC was reported at an increased level. ② The positive expression of HIF-1α was associated with the age and tumor size of OSCC patients (P < 0.05); the positive expression of O-GlcNAc and OGT was related to the tumor size of OSCC patients (P < 0.05). ③ Expression of HIF-1α, O-GlcNAc and OGT in OSCC tissues was positively correlated (φcorrelation coefficient = 0.550). ④ Under HIF-1α inhibition, a statistically significant decrease occurred in the expression levels of O-GlcNAc and OGT at a dose of 25 μM PX-478 (P < 0.05), but a statistically significant increase occurred in OGA (P < 0.05). ⑤ Under the action of PX-478, there was a statistically significant and gradual decrease in the OGT content over time (P < 0.05).
conclusionsThe expression of HIF-1α and O-glycosylation-related proteins increases in OSCC, and the expression level increases proportionally with tumor volume. Expression of HIF-1α and O-GlcNAc and OGT was positively correlated. HIF-1α inhibition by PX-478 led to decreased expression levels of O-GlcNAc and OGT but the increased expression level of OGA. PX-478 can affect Tca8113 glycosylation by reducing the expression level of OGT.
Indexed as
Identifiers
34306413PMC8290824W3184339711What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.